Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $17 from $21 and keeps a Buy rating on the shares. A challenged environment is reflected in guidance, though this was “largely anticipated,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $10 from $17 at Stephens
- OptimizeRx: Strong Q4 Execution, Temporary Headwinds, and Raised Profitability Guidance Support Buy Rating
- OptimizeRx Authorizes $10 Million Share Repurchase Program
- OptimizeRx reports Q4 EPS 51c, consensus 22c
- OptimizeRx sees FY26 revenue $109M-$114M, consensus $121.63M